Barclays PLC Grows Stock Holdings in Prothena Co. plc (NASDAQ:PRTA)

Barclays PLC grew its position in Prothena Co. plc (NASDAQ:PRTA - Free Report) by 110.2% during the 3rd quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 95,222 shares of the biotechnology company's stock after acquiring an additional 49,916 shares during the period. Barclays PLC owned about 0.18% of Prothena worth $1,592,000 at the end of the most recent quarter.

A number of other institutional investors and hedge funds have also made changes to their positions in PRTA. Wellington Management Group LLP boosted its holdings in Prothena by 14.8% in the 3rd quarter. Wellington Management Group LLP now owns 4,178,788 shares of the biotechnology company's stock valued at $69,911,000 after purchasing an additional 539,359 shares in the last quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC lifted its holdings in shares of Prothena by 1,122.9% in the 3rd quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 526,748 shares of the biotechnology company's stock valued at $8,812,000 after buying an additional 483,673 shares during the period. Armistice Capital LLC boosted its stake in shares of Prothena by 42.3% in the second quarter. Armistice Capital LLC now owns 1,560,000 shares of the biotechnology company's stock valued at $32,198,000 after buying an additional 464,000 shares in the last quarter. Duncan Williams Asset Management LLC acquired a new position in Prothena during the third quarter worth $816,000. Finally, Federated Hermes Inc. purchased a new position in Prothena in the second quarter worth $905,000. 97.08% of the stock is currently owned by institutional investors and hedge funds.

Analysts Set New Price Targets

Several equities research analysts have commented on the stock. Chardan Capital initiated coverage on shares of Prothena in a research report on Friday, December 20th. They set a "buy" rating and a $40.00 target price on the stock. HC Wainwright reissued a "buy" rating and set a $48.00 price objective (down previously from $84.00) on shares of Prothena in a report on Friday, December 20th. Bank of America dropped their target price on shares of Prothena from $26.00 to $22.00 and set a "neutral" rating for the company in a report on Thursday, December 19th. Cantor Fitzgerald reiterated an "overweight" rating on shares of Prothena in a research report on Monday, September 30th. Finally, StockNews.com cut Prothena from a "hold" rating to a "sell" rating in a report on Tuesday, November 19th. One investment analyst has rated the stock with a sell rating, two have given a hold rating and five have issued a buy rating to the company's stock. According to MarketBeat, the stock has a consensus rating of "Moderate Buy" and an average target price of $46.50.

Prothena Trading Down 7.8 %

Shares of PRTA stock traded down $1.11 during trading hours on Friday, hitting $13.05. The company's stock had a trading volume of 521,545 shares, compared to its average volume of 479,758. The business has a fifty day moving average of $14.92 and a 200-day moving average of $18.38. Prothena Co. plc has a twelve month low of $11.70 and a twelve month high of $36.20. The stock has a market cap of $702.21 million, a price-to-earnings ratio of -5.26 and a beta of 0.10.

Prothena (NASDAQ:PRTA - Get Free Report) last announced its earnings results on Tuesday, November 12th. The biotechnology company reported ($1.10) EPS for the quarter, beating analysts' consensus estimates of ($1.18) by $0.08. Prothena had a negative return on equity of 24.19% and a negative net margin of 98.86%. The firm had revenue of $0.97 million for the quarter, compared to analysts' expectations of $1.22 million. During the same quarter in the prior year, the firm earned $0.38 EPS. Prothena's quarterly revenue was down 98.9% on a year-over-year basis. On average, equities analysts expect that Prothena Co. plc will post -2.24 EPS for the current fiscal year.

Prothena Profile

Prothena Corporation plc, a late-stage clinical biotechnology company, focuses on discovery and development of novel therapies to treat diseases caused by protein dysregulation in the United States. The company is involved in developing birtamimab, an investigational humanized antibody that is in Phase III clinical trial for the treatment of AL amyloidosis; Prasinezumab, a humanized monoclonal antibody, for the treatment of Parkinson's disease and other related synucleinopathies which is in Phase IIb clinical trial; NNC6019 that is in Phase lI clinical trial for the treatment of ATTR amyloidosis; and BMS-986446 and PRX012, which is in Phase I clinical trial for the treatment of Alzheimer's disease.